© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Invivyd, Inc. (IVVD) stock declined over -11.22%, trading at $0.40 on NASDAQ, down from the previous close of $0.45. The stock opened at $0.46, fluctuating between $0.40 and $0.46 in the recent session.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Employees | 94 |
Beta | 0.66 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Invivyd, Inc. (NASDAQ: IVVD) stock price is $0.40 in the last trading session. During the trading session, IVVD stock reached the peak price of $0.46 while $0.40 was the lowest point it dropped to. The percentage change in IVVD stock occurred in the recent session was -11.22% while the dollar amount for the price change in IVVD stock was -$0.05.
The NASDAQ listed IVVD is part of Biotechnology industry that operates in the broader Healthcare sector. Invivyd, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Laura Walker Ph.D.
Co-Founder & Chief Scientific Officer
Ms. Jill Andersen J.D.
Chief Legal Officer & Corporation Sec.
Mr. David Hering M.B.A.
Chief Executive Officer & Director
Ms. Kyra Rosow Faircloth M.S.
Vice President of Gov. Affairs, Advocacy & Corporation Communication
Ms. Stacy Price
Chief Technology & Manufacturing Officer
Dr. Elham Hershberger Pharm.D.
Chief Devel. Officer
Mr. Jeremy Gowler
Chief Operating Officer & Chief Commercial Officer
Kyra Rosow Faircloth
Vice President of Gov. Affairs, Advocacy & Corporation Communication
Dr. Rebecca Dabora Ph.D.
Chief Technology & Manufacturing Officer
Ms. Stacy Price M.S.
Chief Technology & Manufacturing Officer
Dr. Peter Schmidt M.D.
Chief Medical Officer
Dr. Peter C. Schmidt M.D., M.S., M.Sc.
Chief Medical Officer
Ms. Heidi Spurling M.S.
Vice President of Strategy & Operations and Chief of Staff to the Chief Executive Officer
Dr. Peter C. Schmidt M.D., M.Sc.
Chief Medical Officer
Ms. Kyra Rosow Faircloth
Vice President of Gov. Affairs, Advocacy & Corporation Communication
Ms. Julie Green M.B.A.
Senior Vice President of HR
Lukas Dillinger Ph.D.
Interim Head of Discovery & Pre-Clinical
Mr. Frederick W. Driscoll
Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Ms. Heidi Spurling
Vice President of Strategy & Operations and Chief of Staff to the Chief Executive Officer
Dr. Robert D. Allen Ph.D.
Chief Scientific Officer
IVVD's closing price is 11.88% higher than its 52-week low of $0.40 where as its distance from 52-week high of $5.20 is -91.3%.
Number of IVVD employees currently stands at 94.
Official Website of IVVD is: https://adagiotx.com
IVVD could be contacted at phone 781 819 0080 and can also be accessed through its website. IVVD operates from 1601 Trapelo Road, Waltham, MA 02451, United States.
IVVD stock volume for the day was 994.53K shares. The average number of IVVD shares traded daily for last 3 months was 1.01M.
The market value of IVVD currently stands at $48.00M with its latest stock price at $0.40 and 119.62M of its shares outstanding.